EGFR and lung adenocarcinoma: The BEYOND study showed that OS was increased by 6.6 months (24.3 vs. 17.7 months) and ORR was increased by 28% (54% vs. 26%) in a group of unselected lung adenocarcinoma patients (including some EGFR-sensitive mutation-positive patients) [33].